NR1H4 and hyperlipidemia: Previous studies have demonstrated that FXR agonists improve hyperglycemia and hyperlipidemia in diabetic mice by inhibiting liver gluconeogenesis and enhancing insulin sensitivity by increasing liver glycogen synthesis and glycogen content (42, 43).